Fierce Pharma

MAY 3, 2024

Shortly after Novo Holdings’ parent company elected to resubmit paperwork around the investment firm’s proposed $16.5 billion buyout of CDMO giant Catalent, the U.S. | Shortly after Novo Holdings’ parent company elected to resubmit paperwork around the investment firm’s proposed $16.5 billion buyout of CDMO giant Catalent, the U.S. Federal Trade Commission has teed up a further extension on the deal’s review period.

257

257

MedCity News

MAY 3, 2024

Hospitals’ operating margins and patient volumes dropped slightly in March. While hospitals were doing relatively well financially during the first quarter of the year, this new data could suggest more financial challenges ahead for hospitals. But right now, it’s unclear whether the recent declines in hospitals’ margins and volumes will be short- or long-term.

Patients 119

Patients 119

Fierce Pharma

MAY 3, 2024

During the Q&A portion of Amgen’s quarterly conference call Thursday, eight of the first nine questions were about the company’s investigational efforts in obesity. | The buzz about Amgen’s obesity prospects overshadowed the company’s solid work on the top line as revenue came in at $7.4 billion for a 22% increase. Much of the boost can be attributed to sales of products acquired in Amgen’s $27.8 billion buyout of Horizon Therapeutics, which was completed early in the fourth quarter of last

Prospecting 228

Prospecting Sales 228

MedCity News

MAY 3, 2024

Amgen is confident its injectable obesity drug would have a differentiated profile compared to medications now on the market from Novo Nordisk and Eli Lilly and it’s now preparing for Phase 3 testing. But an oral obesity drug in Amgen’s pipeline will not advance beyond Phase 1. The post Amgen Puts Its Weight Behind Obesity Drug With Potential Edge Over Lilly, Novo Nordisk Meds appeared first on MedCity News.

Medical 113

Medical Marketing Biopharma Pharma 113

Advertisement

What if you could help your sellers stop wasting 72% of their day on non-selling activities and focus on bringing in revenue? Incorporating AI in your enablement workflows can help you cut down on busy work, get projects done faster, and let your team (and you!) focus on making a bigger impact. We put together this guide to show you how to use AI to cut time and costs for projects, including collateral creation, development of training videos, and automating tedious processes.

Sales Management

Fierce Pharma

MAY 3, 2024

Watch out, Incyte. Leo Pharma and its JAK inhibitor cream delgocitinib are coming to disrupt the topical atopic dermatitis market, currently inhibited by Incyte’s approved Opzelura. | Leo Pharma's delgocitinib, which the company calls a potential growth driver, could shake up the topical JAK market and put pressure on Incyte's approved Opzelura.

Marketing 226

Marketing Pharma 226

Pharmaceutical Technology

MAY 3, 2024

UK liquid biopsy company, Angle, has agreed a supplier agreement with AstraZeneca to develop a Parsotix-based Androgen Receptor (AR) assay for use in prostate cancer studies.

104

104

pharmaphorum

MAY 3, 2024

Walgreens’ plans to disrupt the clinical trials sector have taken a step forward with a high-profile partnership with Boehringer Ingelheim

133

133

MedCity News

MAY 3, 2024

Lawmakers have ghost networks in their sights, and payers can prepare now for policy changes. The post Navigating Policy Terrain: Perspectives for Payers on Tackling Ghost Networks appeared first on MedCity News.

Networking 103

Networking 103

European Pharmaceutical Review

MAY 3, 2024

In final draft guidance , the National Institute For Health and Care Excellence (NICE) has recommended voxelotor (Oxbryta) with or without hydroxycarbamide as a treatment for haemolytic anaemia, which is caused by sickle cell disease. According to NICE, around 4,000 people aged 12 years and older with sickle cell disease in England will be able to benefit from the treatment.

Food and Drug Administration 98

Food and Drug Administration Medicine Food Patients 98

MedCity News

MAY 3, 2024

Offering blended options, individual risk pools, and net neutral capitation payments providers can embark on their journey toward value-based care at a pace aligned with their tolerance and readiness. The post Navigating the Transition to Value-Based Care: Addressing Fears and Embracing Risk in ACO REACH appeared first on MedCity News.

Healthcare 103

Healthcare Healthcare 103

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

Patients

European Pharmaceutical Review

MAY 3, 2024

An interim analysis of a Phase III trial of Calquence (acalabrutinib) plus chemoimmunotherapy has revealed positive progression-free survival outcomes for adults with untreated mantle cell lymphoma. AstraZeneca ’s ECHO Phase III trial evaluated acalabrutinib in combination with standard-of-care chemoimmunotherapy , bendamustine and rituximab. Calquence (acalabrutinib) is a next-generation, Bruton’s tyrosine kinase (BTK) inhibitor.

Safety 98

Safety Patients Medicine Medical 98

pharmaphorum

MAY 3, 2024

Apple gets FDA okay to use the atrial fibrillation history tool incorporated in some of its Apple Watch devices in clinical trials

FDA 126

FDA 126

Pharmaceutical Technology

MAY 3, 2024

The FDA has awarded the designation following a review of initial safety and efficacy data from two Phase I/II clinical trials.

FDA 105

FDA Safety 105

pharmaphorum

MAY 3, 2024

Some NHS patients in the UK will finally be able to access Pfizer’s sickle cell disease therapy Oxbryta after agreement was reached on a price cut

Patients 118

Patients 118

Advertisement

Every marketer knows how important it is to prove their efforts drive sales opportunities, but that’s easier said than done. When problems like sales and marketing misalignment, lack of data, and wasted efforts persist, marketers can’t measure, prove, or increase their impact on revenue at a time when demonstrating marketing value is critical. Using analyst and expert data, this guide to marketing impact and content attribution explains: How B2B buyers use content The most common types of conten

Sales

Pharmaceutical Technology

MAY 3, 2024

Moderna reported a net loss of $1.2bn in the first quarter (Q1) of 2024, a stark contrast to its net income of $79m in Q1 2023.

99

99

PharmaTech

MAY 3, 2024

In this exclusive Drug Digest video interview, Chris Spivey, Director, Industry Relations and Strategic Partnerships, talks with industry experts about various aspects of drug product stability testing.

72

72

Pharmaceutical Technology

MAY 3, 2024

The NHS in the UK has announced plans to offer Pfizer's Voxelotor (Oxbryta), a new treatment option for sickle cell disease.

98

98

PharmaTimes

MAY 3, 2024

The INTerpath-001 trial is evaluating Moderna/Merck’s mRNA-4157 in combination with Merck’s Keytruda

Recruitment 101

Recruitment Patients 101

Advertisement

Pharmaceutical Technology

MAY 3, 2024

Amgen announced updates in the obesity space, with topline data for MariTide expected in late 2024.

98

98

PharmaTimes

MAY 3, 2024

Neurological disorders, such as epilepsy or chronic pain, affect over three billion people worldwide

97

97

pharmaphorum

MAY 3, 2024

AI-powered home healthcare model from Cera could save NHS and UK £1bn in 2026 if adopted nationwide, says new study

Healthcare 108

Healthcare Healthcare 108

Pharmaceutical Commerce

MAY 3, 2024

The latest news for pharma industry insiders.

Pharma 105

Pharma Patients 105

Advertisement

Quotas need to be hit. Revenue goals need to be met. This reality makes shortening sales onboarding time a top priority. Organizations with a standard onboarding process boost employee retention by 58% and increase productivity by 50%. Unfortunately, many companies struggle with inefficient processes that lead to high turnover and missed revenue opportunities.

Sales

PharmaVoice

MAY 3, 2024

With its next earnings report looming, pushback from an investor is adding pressure on Novavax to boost performance.

Pharma 72

Pharma 72

Pharmaceutical Technology

MAY 3, 2024

Techniques such as rapid nanomotion-based susceptibility testing, and MALDI-TOF-MS could be used to identify resistance mechanisms of several deadly organisms.

59

59

Clarify Health

MAY 3, 2024

This is part two of our three-part series about how health plan leaders can leverage healthcare claims data to reduce costs , strategically grow their networks , provide best-in-class member services , and enhance outcomes for their members. In the era of digital transformation, healthcare claims data stands out as a critical asset health plans can use to optimize their network performance.

Networking 52

Networking Healthcare Healthcare Healthcare Provider 52

Rep-Lite

MAY 3, 2024

Medical sales reps who consistently goes above and beyond is the dream of any company. When medical sales jobs and cutting-edge technologies meet the ever-evolving healthcare needs, having a top-performing team is a necessity. These high-caliber medical sales reps are the bridge between innovative solutions and the medical professionals who can leverage them to improve patient care.

Medical sales reps 52

Medical sales reps Medical sales Sales Medical 52

Advertisement

Distribution

PharmExec

MAY 3, 2024

In an interview with Pharm Exec Associate Editor Don Tracy, Melissa Lattanzi, VP, Emerging Therapies, Cencora, offers a synopsis on what questions cell and gene therapy developers need to answer to inform their distribution strategy.

Distribution 52

Distribution 52

Pharmaceutical Commerce

MAY 3, 2024

Collaboration will be oncology based—centered around allogeneic CAR-T cell therapy product candidates—and will provide Poseida with up to $550 million if certain milestones are met.

52

52

PharmExec

MAY 3, 2024

In this Pharmaceutical Executive video interview, Jesse Mendelsohn, senior vice president at Model N, talks about the influence of Medicare Part D drug price negotiations on manufacturer go-to-market strategies and decision-making, and the industry’s response to the wider dialogue on pricing transparency.

Manufacturing 52

Manufacturing Pharmaceutical Marketing 52

Pharmaceutical Commerce

MAY 3, 2024

Per the US strategic partnership agreement, the adalimumab high-concentration interchangeable biosimilar will be distributed under the Quallent Pharmaceuticals private label.

Distribution 52

Distribution Pharmaceutical 52

Advertisement

Are your sellers unsure about using AI in their day-to-day workflows? Or are they eager to try but uncertain where to start? They might be asking: Which tasks are best suited for AI? How will using AI affect my relationship with my customers? With so many tools available, which ones are the most useful to me? To help answer these and other common questions about using AI during the sales cycle, we surveyed B2B sellers who were early adopters to get their insight and advice about how to use gen A

Sales